Drug Profile
TX 397
Latest Information Update: 08 Feb 2018
Price :
$50
*
At a glance
- Originator Theramex SAM
- Class Antineoplastics
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Endometriosis; Prostate cancer
Most Recent Events
- 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex
- 20 Dec 1999 Théramex SAM acquired by Merck KGaA
- 21 May 1998 Preclinical development for Breast cancer in Europe (Unknown route)